Background/Aims: Calycosin, a phytoestrogenic compound, has recently emerged as a promising antitumor drug. It has been shown that calycosin suppresses growth and induces apoptosis of breast cancer cells. However, the effect of calycosin on migration and invasion of breast cancer cells and the underlying molecular mechanisms have not been elucidated. Methods: Human breast cancer cells MCF-7 and T47D were treated with, or without, different doses (0, 6.25, 12.5, 25, 50, 100 or 150 μM) of calycosin, and the viability of different groups was determined by MTT assay. Next, the inhibitory effect of higher doses (50, 100 or 150 μM) of calycosin on migration and invasion of the two cell lines was determined by wound healing and transwell assay. The relative expression levels of forkhead box P3 (Foxp3), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in MCF-7 and T47D cells were determined by quantitative RT-PCR and Western blot. Results: Treatment with lower doses (6.25 or 12.5 μM) promoted proliferation of breast cancer cells, but with higher doses significantly reduced the viability of MCF-7 and T47D cells. Furthermore, higher doses of calycosin were found to inhibit migration and invasion of the two cell lines in a dose-dependent manner. Additionally, treatment with a higher dose of calycosin significantly reduced the expression levels of Foxp3, followed by down-regulation of VEGF and MMP-9 in both MCF-7 and T47D breast cancer cells. Conclusion: Treatment with a higher dose of calycosin tends to reduce migration and invasion capacity of human breast cancer cells, by targeting Foxp3-mediated VEGF and MMP-9 expression.
Introduction
Breast cancer remains a serious health threat for women and its incidence is increasing worldwide [1] . For example, in China, breast cancer is the most common cancer among women, with more than 1.6 million new cases being diagnosed each year [2] . Although new therapeutic strategies have significantly improved the survival rates of breast cancer patients, these have either limited effect on breast cancer patients with distant metastasis or none at all. Furthermore, many therapeutic strategies are accompanied by resistance and severe side effect, affecting the quality of patient's life [3, 4] . Therefore, development of new therapeutic reagent for breast cancer will be of significance, especially one that can suppress tumor metastasis.
Notably, there is a relatively lower incidence of breast cancer in Asian women in comparison with Western women, which may be associated with consumption of many leguminous plants [5] . Leguminous plants are a major source of vegetable protein. Also phytoestrogens, natural non-steroid compounds, are widely present in them. Phytoestrogens are structurally similar to estrogen in mammal, and can act as estrogenic agonist or antagonist by binding to estrogen receptor (ER) [6] . Many phytoestrogens such as isoflavones, lignans and coumestrol are known to inhibit the growth of malignant tumors (e.g. breast cancer, prostate cancer, ovarian cancer, and others) [7] [8] [9] . For example, numerous in vitro studies have shown that the soy isoflavones genistein and formononetin inhibit breast cancer cell proliferation and trigger apoptosis by targeting the signaling pathways of NF-κB, PI3K/Akt/ mTOR or MAPK/ERK [10] .
Calycosin (C 16 H 12 O 5 ), another effective isoflavones isolated from Astragali Radix, is widely used as a crude compound for its various biological effects such as antioxidative, anti-inflammation and even anti-tumor activities [11, 12] . In our previous study, calycosin has been proved to inhibit proliferation and induce apoptosis of breast cancer and colorectal cancer cells expressing ER; this effect may be mediated by the regulation of ER signaling and its interaction with microRNAs (miRNAs) [13, 14] . However, it is unclear whether calycosin can modulate migration and invasion of ER-positive human breast cancer cells. Therefore, this study was designed to evaluate the anti-metastatic effect of calycosin and its possible mechanism of action in ER-positive MCF-7 and T47D breast cancer cells.
The forkhead box P3 (Foxp3) is a transcription factor and critical for the function regulatory T cells (Tregs). Foxp3 was initially thought to be expressed specifically in Tregs, and has been recently reported to be expressed in tumor cells including breast cancer [15] . It has been shown that Foxp3 is highly expressed in ER-positive breast cancer cells, and the high expression levels in breast cancer tissues are positively associated with histological grades and metastasis [16, 17] . Meanwhile, Foxp3 is proved to regulate vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) expression in MCF-7 cells [18] . In particularly, down-regulation of Foxp3 was reported to inhibit invasion of cholangiocarcinoma cell lines by reducing the levels of MMP-9 and MMP-2 [19] . In consequence, we here determine the role of Foxp3-mediated signaling in the migration and invasion of breast cancer cells, which may be involved in calycosin-induced inhibitory effects on ER-positive breast cancer. This work provides the insight into the effects of calycosin on metastatic breast cancer.
Materials and Methods

Cell culture
Human breast cancer MCF-7 and T47D cells were purchased from Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China. The cells were cultured in DMEM medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Invitrogen), 100 units/ml penicillin and 100 µg/ml streptomycin at 37 °C, 5% CO 2 . Wound healing assay MCF-7 and T47D cells were cultured in 24-well plates (5×10 4 cells/well). After 24 h, a 10 µl pipette tip was used to scratch the monolayer of confluent cells. Next, cells were cultured in triplicate in FBS-free medium in the absence or presence of different concentration (50, 100 or 150 μM) of calycosin. Wound closure was quantified by measuring the average width of the wounds using Image J software (NIH, Bethesda, MD, USA) at 0, 24 or 48 h. The migration inhibitory rate were calculated by the following formula: migration distance=(wound width at the beginning -wound width after treatment)/2 (μm); migration inhibitory rate=(average migration distance in the control group -average migration distance in the treatment group)/average migration distance in the control group ×100%.
Transwell assay
The migration of MCF-7 and T47D cells was performed using a 24-well transwell chamber (8 µm pore size; Millipore, Billerica, MA, USA). The cells were plated in triplicate into the upper chamber (1 × 10 5 cells/ well) in the presence or absence of different concentrations (50, 100 or 150 μM) of calycosin for 24 h. The bottom chambers were added with DMEM containing 10% FBS. Then non-migrated cells remaining on the upper surface of the membrane were removed using a cotton swab, and the migrated cells on the bottom surface were fixed with 4% paraformaldehyde, staining with crystal violet and photographed under a microscope. The numbers of migrated cells were counted in 5 randomly-selected fields for each chamber.
Real-time PCR assay
MCF-7 and T47D cells were treated in triplicate with or without calycosin (50, 100 or 150 μM) for 48 h. Their total RNA was extracted using TRIzol reagents (Invitrogen) and reversely transcribed into cDNA using a Revert Aid First Strand cDNA Synthesis Kit (Fermentas, Hanover, MD, USA). The relative levels of Foxp3, V E G F a n d MMP-9 to control GAPDH mRNA transcripts were measured by quantitative RT-PCR using specific primers and the SYBR Green qPCR Master Mix (Fermentas). The data were calculated using the ABI 7500 software v2.0.1 (Applied Biosystems, Waltham, MA, USA).
Western blotting assay MCF-7 and T47D cells were treated in triplicate with or without calycosin at concentrations of 50, 100 or 150 μM for 48 h. The cells were harvested and lysed in cell lysis buffer. The cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF; Milipore) membranes. After being blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween 20 (TBST), the members were incubated with primary antibodies against Foxp3, MMP-9, VEGF and GAPDH (1:1000, Abcam, Cambridge, UK) overnight at 4 ºC. ECL detection systems (Thermo Scientific, Rockford, IL, USA) were utilized to visualize the specific binding. The relative levels of target proteins to the control GAPDH were determined by image pro plus 5.02 software (Media Cybernetics, Bethesda, MD, USA).
Statistical analysis
Data are expressed as mean±SD. The difference among groups was determined by one-way ANOVA tests using SPSS version 12.0 for Windows (IBM SPSS Statistics, Chicago, IL, USA). A p-value of < 0.05 was considered statistically significant.
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Results
Calycosin affects the survival of breast cancer cells in a dose-dependent manner
To determine effect of calycosin on the proliferation of ER-positive breast cancer, MCF-7 and T47D cells were treated in triplicate with, or without, different doses of calycosin for 48 h. The viability of cells was determined by MTT assay. As shown in Fig. 1 , treatment with calycosin at lower doses (6.25 or 12.5 μM) significantly enhanced the survival of MCF-7 and T47D cells (p < 0.05). In contrast, at the higher doses (50, 100 or 150 μM), calycosin induced dose-dependent inhibition on viability of the both two cell lines (p < 0.05 or p < 0.01). Hence, lower dose of calycosin promoted proliferation of breast cancer cells MCF-7 and T47D, while calycosin at a higher dose exhibited cytotoxicity against them. the two cell lines were treated with high doses of calycosin (50, 100 or 150 µM) for 0, 24 or 48 h, and subjected to wound healing and transwell migration assays. Cells without calycosin treatment gradually reduced the wound width with extending time, while the relative change in wound width of both MCF-7 and T47D cells was decreased in the presence of calycosin, in a dose-and time-dependent manner ( Fig. 2A ). Quantitative analysis indicated that different concentrations of calycosin (50, 100 or 150 µM) after 48 h treatment respectively reduced the migration of MCF-7 cells by 22.2%, 57.6% and 60.6%, and T47D cells by 45.3%, 63% and 71.8% (p < 0.05 or p < 0.01, Fig. 2B ). Further analysis revealed that treatment with higher doses of calycosin significantly reduced the numbers of invaded cells and its effects appeared to be dose-dependent (p < 0.05 or p < 0.01, Fig. 3) . Thus, our results suggest that treatment with higher doses of calycosin could lead to significant inhibition of migration, motility and invasion of ER-positive breast cancer cells, consistent with its cytotoxicity against MCF-7 and T47D cells.
Treatment with higher doses of calycosin inhibits migration and invasion of breast cancer cells
Based on MTT, calycosin exerted inhibitory effects on MCF-7 and T47D cells at relatively high doses. To test whether calycosin can reduce breast cancer cell motility and migration,
Treatment with higher doses of calycosin reduces the expression of Foxp3 in breast cancer cells
To understand the potential mechanisms underlying the anti-metastatic effects of calycosin in breast cancer, MCF-7 and T47D cells were treated in triplicate with calycosin 
Treatment with higher doses of calycosin inhibits the expression of VEGF and MMP-9 in breast cancer cells
Previous studies have linked Foxp3 expression to the VEGF and MMP-9 signaling molecules that play important role in invasion and metastasis of malignant tumors [18] . We here found that the mRNA and protein levels of VEGF and MMP-9 were also dose-dependently reduced by calycosin in breast cancer cells MCF-7 and T47D, consistent with the decreased Foxp3 expression pattern (p < 0.05 or p < 0.01, Fig. 5 ). At the highest concentration of 150 µM, the mRNA and protein expression levels of VEGF were respectively decreased by 36.6% and 72% in MCF-7 cells, while 89.5% and 81.4% in T47D cells. As for MMP-9 levels in MCF-7 and T47D cells, 150 µM calycosin treatment respectively reduced mRNA expression by 42.1% and 65.8%, and protein synthesis by 59.6% and 49.2%.
Discussion
According to the American Society of Clinical Oncology (ASCO), women with ER-positive breast cancer accounts for approximately 60% to 75% of US women with breast cancer [20] . Moreover, calycosin is proved to possess estrogenic or anti-estrogenic activities by modulating the ER signaling pathways, indicating its potential applications in treating ERpositive breast cancer [21] . Given that high level of ER is expressed on human breast cancer cells MCF-7 and T47D, in present study, we focused on the effect of calycosin on migration and invasion of MCF-7 and T47D cells.
First, as expected, treatment with a lower dose of calycosin promoted cell growth, while treatment with a higher dose of calycosin significantly reduced the viability of both MCF-7 and T47D cells. One possible reason for this is that calycosin has estrogenic or antiestrogenic effects depending on concentration. Here the two cell lines were exposed to high doses of calycosin, thus the ERβ-but not ERα-mediated signaling pathway was activated, leading to inhibition of breast cancer proliferation [22] . Accordingly, we chose relatively high doses of calycosin (50, 100 or 150 μM) for further study. Cell migration and invasion are important processes in tumor development and metastasis [23] . However, there is limited evidence for the potential activity of calycosin against both migration and invasion in breast cancer cells, not to mention the mechanism underlying it. In present study, it was found that calycosin dose-dependently inhibited invasiveness and metastasis of MCF-7 and T47D cells, indicating that calycosin may be a promising anti-tumor drug for treatment of breast cancer. It is well known that MMPs are crucial for the process of invasion and metastasis of cancer cells, and VEGF is important for inducing vascularization [24, 25] . Indeed, increased levels of MMPs and VEGF have been confirmed to associate positively with invasion and [27, 28] . Thus, we first investigated whether calycosin had a similar effect on MMP-9 and VEGF expression in our settings. The results showed that calycosin downregulated the expression of MMP-9 and VEGF at both mRNA and protein levels in the two breast cancer cell lines in a dose-dependent manner. The next question concerns the molecular mechanism through which calycosin acquire decreased expression of MMP-9 and VEGF. Jou et al. reported that Foxp3, a member of the forkhead/winged-helix family of transcription regulators, enhances expression of VEGF by binding with hypoxia-inducible factor-1α (HIF-1α) [29] . Thus, we evaluated levels of Foxp3 in calycosin-treated MCF-7 and T47D cells. It was found that treatment with a higher dose of calycosin also significantly attenuated the levels of Foxp3 expression, which was consistently related to VEGF and MMP-9 levels. In this regard, we believe that the down-regulation of Foxp3 reduced expression of VEGF and MMP-9 in these cells. This contributes to inhibition of migratory and invasive activity of human breast cancer cells.
However, there have been conflicting reports regarding Foxp3 function in cancers. Although, some previous studies have suggested that Foxp3 acts a tumor suppressor in the breast gland, Merlo et al. identified Foxp3 as a poor prognostic factor in breast carcinoma for distant metastases, and expression of Foxp3 in breast tumors was inversely associated with survival rate [30] [31] [32] . Similarly, we here demonstrated that calycosin-mediated inhibition of cell migration and invasion was accompanied with the down-regulated expression of Foxp3 in MCF-7 and T47D cells. This result provides evidence that Foxp3 could be relevant for breast cancer cell migration, supporting the idea that Foxp3 could act as a tumor promoter.
Conclusion
In summary, the present study indicated that the phytoestrogen calycosin attenuates migration and invasion of MCF-7 and T47D cells. Such action likely involves inhibition of Foxp3 expression, which then down-regulates the levels of VEGF and MMP-9. Our findings may provide new insights into molecular mechanisms underlying the anti-carcinogenic properties of calycosin on ER-positive breast cancer cells. Hence, calycosin may be valuable for development of new therapies for ER-positive breast cancer.
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